Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Fresolimumab||GC1008||TGFB (Pan) Antibody 3||Fresolimumab (GC1008) is a monoclonal antibody that binds TGFB1, TGFB2, and TGFB3, blocking receptor interaction and signaling, which may inhibit proliferation and metastasis of cancer cells (PMID: 24618589, PMID: 31296256).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||melanoma||not applicable||Fresolimumab||Phase I||Actionable||In a phase I clinical trial, Fresolimumab (GC1008) demonstrated safety and preliminary evidence of antitumor activity in patients with malignant melanoma (PMID: 24618589).||24618589|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02581787||Phase Ib/II||Fresolimumab||SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer||Active, not recruiting||USA||0|